Protea Biosciences Group Inc. announced that it is collaborating with Agilent Technologies Inc. to address customer challenges within existing Biopharma bioanalytical workflows in order to meet the emerging needs of the growing biopharmaceutical industry. Under Terms of the Agreement, a Memorandum of Understanding (MOU), Protea, using Agilent instrumentation combined with its technology, will develop workflows that focus on developing new methods for the field of metabolomics.